KR101655882B1 - Composition for eliminating hangover comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient - Google Patents
Composition for eliminating hangover comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient Download PDFInfo
- Publication number
- KR101655882B1 KR101655882B1 KR1020150141422A KR20150141422A KR101655882B1 KR 101655882 B1 KR101655882 B1 KR 101655882B1 KR 1020150141422 A KR1020150141422 A KR 1020150141422A KR 20150141422 A KR20150141422 A KR 20150141422A KR 101655882 B1 KR101655882 B1 KR 101655882B1
- Authority
- KR
- South Korea
- Prior art keywords
- hangover
- culture
- weight
- extracellular polysaccharide
- mycelial
- Prior art date
Links
- 206010019133 Hangover Diseases 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 239000004480 active ingredient Substances 0.000 title claims abstract description 14
- 241001466515 Emmia lacerata Species 0.000 title claims abstract description 4
- 229920002444 Exopolysaccharide Polymers 0.000 title description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 121
- 150000004676 glycans Chemical class 0.000 claims abstract description 37
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 37
- 239000005017 polysaccharide Substances 0.000 claims abstract description 37
- 239000007788 liquid Substances 0.000 claims abstract description 26
- 239000000843 powder Substances 0.000 claims abstract description 25
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims abstract description 24
- 210000004369 blood Anatomy 0.000 claims abstract description 24
- 239000008280 blood Substances 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 230000036541 health Effects 0.000 claims abstract description 13
- 235000013376 functional food Nutrition 0.000 claims abstract description 11
- 239000001963 growth medium Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 13
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 230000001461 cytolytic effect Effects 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000001569 carbon dioxide Substances 0.000 claims description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 6
- 238000009630 liquid culture Methods 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- 241001122767 Theaceae Species 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000013312 flour Nutrition 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 235000019441 ethanol Nutrition 0.000 description 46
- 239000000243 solution Substances 0.000 description 23
- 230000035622 drinking Effects 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- 230000006872 improvement Effects 0.000 description 13
- 239000001965 potato dextrose agar Substances 0.000 description 12
- 239000000902 placebo Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 8
- 230000002265 prevention Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 244000287680 Garcinia dulcis Species 0.000 description 5
- 241001440188 Lacera Species 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000005227 gel permeation chromatography Methods 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 244000061428 Laplacea serrata Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940060799 clarus Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000003988 headspace gas chromatography Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108010033145 microsomal ethanol-oxidizing system Proteins 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A23L1/30—
-
- A23L1/3058—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/195—Proteins from microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Abstract
The present invention relates to an extracellular polysaccharide produced by Ceriporia lacerata ; A mycelial culture solution of ceriplora lacerata containing the extracellular polysaccharide; A dry powder of the mycelial culture liquid; Or an extract of the mycelial body culture liquid as an active ingredient. The composition of the present invention is excellent in the effect of reducing hangover by reducing ethanol or acetaldehyde in blood, thereby preventing or preventing hangover A pharmaceutical composition and a health functional food for preventing or improving hangover.
Description
The present invention relates to an extracellular polysaccharide produced by Ceriporia lacerata ; A mycelial culture solution of ceriplora lacerata containing the extracellular polysaccharide; A dry powder of the mycelial culture liquid; Or an extract of the mycelial culture liquid as an active ingredient.
A hangover usually refers to a condition in which the head is heavy, sore or tired due to drinking, which is caused by the poisoning of ethanol or acetaldehyde accumulated in the hepatocytes will be. If these substances accumulate in hepatocytes for a long period of time and persists, toxicity, abdominal bloating, and vomiting will occur.
In normal ethyl alcohol metabolism, the ethyl alcohol introduced into the body is absorbed from the stomach or small intestine and is transferred into the blood vessels and transferred to the liver. The hepatocytes have alcohol dehydrogenase (ADH), which oxidizes the alcohol to acetaldehyde And the acetaldehyde is decomposed into acetic acid by acetaldehyde dehydrogenase (ALDH) in hepatocytes and transferred to muscle or fat tissue of the whole body and finally decomposed into carbon dioxide gas and water. The acetaldehyde dehydrogenase also has type II, which initiates oxidation even when acetaldehyde is low in concentration, and type I, which does not act unless the concentration of acetaldehyde is high. Since Asians generally have a deficiency or lack of type II acetaldehyde dehydrogenase, the oxidation of acetaldehyde is slow and therefore the normal metabolism is inhibited by the toxic action of unoxidized acetaldehyde and / or ethyl alcohol. do.
On the other hand, ethanol is the main component of alcohol, and the ethanol that is ingested is absorbed through the small intestine and digestive tract and reaches the highest blood concentration within 20 to 120 minutes after ingestion. The ethanol thus absorbed is metabolized in all organs including liver, Approximately 10% of these are excreted by breathing, or urine and sweat, and most of the rest is broken down in the liver.
The ethanol degradation in the liver is the main metabolism by oxidation to acetaldehyde. It is known that this is caused by three reactive enzyme systems such as ADH, microsomal ethanol-oxidizing system and catalase (K. Ebihara et al., Agri . Biol . Chem. , 52, 1311 , 1988). In addition to the mechanism of ethanol degradation, various toxicological studies have been conducted. It has been reported that the toxicity of ethanol is not only observed neurologically but also genetically (J. Caballeria, et al., Life Sci . , 41, 1021-1727, 1986).
In recent years, many researches and experiments have been conducted on a number of substances that can reduce the toxicity of ethanol or inhibit the expression of toxins. As a result, various dietary supplements containing ingredients extracted from natural or herbal ingredients Which is being developed. As a part of this research, Korean Patent No. 10-0968109 discloses a composition for removing hangover comprising a natural extract and a calcium compound and a method for producing the same.
On the other hand, Sellapora lacerata is a kind of white rot fungus, and it is known that it performs co-metabolism called lignin decomposition in order to utilize carbon sources such as cellulose, hemicellulose, other polysaccharides and glycerol in an ecosystem.
Regarding the medical treatment application using the serpia lacrosera, Korean Patent Registration No. 10-1031605 filed by the present inventors has only known heretofore for the diabetes treatment of the extract of the culture liquid of Serrachia lacera rata , And the effect of hangover relief by using three lipolas lacerata has not been reported yet.
Accordingly, the present inventors have found that an extracellular polysaccharide separated from a cerporolactacera; A mycelial culture solution of ceriplora lacerata containing the extracellular polysaccharide; A dry powder of the mycelial culture liquid; Or the extract of the mycelium culture solution shows a hangover resolution effect, thereby completing the present invention.
It is an object of the present invention to provide a hangover lozenges composition containing an active ingredient produced by ceriplora lactaclora; A pharmaceutical composition for prevention or elimination of hangover comprising the same, or a health functional food for preventing or improving hangover.
In order to accomplish the above object, the present invention provides an extracellular polysaccharide produced by a cellulolytic enzyme; A mycelial culture solution of ceriplora lacerata containing the extracellular polysaccharide; A dry powder of the mycelial culture liquid; Or an extract of the mycelial culture liquid as an active ingredient.
An extracellular polysaccharide produced by a cellulolytic enzyme according to the present invention; A mycelial culture solution of ceriplora lacerata containing the extracellular polysaccharide; A dry powder of the mycelial culture liquid; Or an extract of the mycelial body as an active ingredient has the effect of reducing ethanol and / or acetaldehyde in blood to resolve hangover, whereby the composition is useful as a pharmaceutical composition for prevention or elimination of hangover, And can be used as a health functional food for prevention or improvement of hangover.
Fig. 1 shows the results of measurement of blood alcohol concentration after treatment of a culture medium of Sellapora lactaceras mycelia.
FIG. 2 is a result of measurement of the hangover resolution of the culture medium of the seripositive L. serrata mycelium in a clinical experiment.
Hereinafter, the present invention will be described in detail.
The present invention relates to an extracellular polysaccharide produced by a cellulolytic enzyme; A mycelial culture solution of ceriplora lacerata containing the extracellular polysaccharide; A dry powder of the mycelial culture liquid; Or an extract of the mycelial culture liquid as an active ingredient.
Wherein the extracellular polysaccharide comprises 40 to 60 wt% sugar, 30 to 40 wt% protein, 40 to 50 wt% sugar, 32 to 38 wt% protein, 43 to 47 wt% sugar, 33 to 36 wt% Of the protein, or about 45 wt% sugar and about 34 wt% protein.
The sugar may contain mannose, galactose and glucose.
The extracellular polysaccharide may have a molecular weight of 100 to 150 kDa, 110 to 140 kDa or 115 to 125 kDa, and more specifically about 120 kDa.
As an embodiment of the present invention, the extracellular polysaccharide may be prepared by: (a) liquid culturing mycelia lacticera mycelium to prepare a culture medium of a seriposita lactamera mycelium; (b) drying and cultivating the culture medium of the above-mentioned sera lipolactacera mycelium; And (c) a step of extracting the culture medium of the cultured Mycelium lacticera mycelium with a solvent, followed by filtration and concentration under reduced pressure.
The medium for liquid culture of the mycelium of seripositive Lactacera in the step (a) is selected from the group consisting of sugar, glucose, starch, water, barley, soybean powder, magnesium sulfate (MgSO 4 ), potassium monophosphate (KH 2 PO 4 ), potassium diphosphate (K 2 HPO 4 ) and water, and the hydrogen ion concentration may be pH 4.5 to 6.0.
Specifically, the culture medium contains 0.2 to 3% by weight of sugar, 0.2 to 3% by weight of glucose, 0.2 to 4% by weight of starch, 0.1 to 0.5% by weight of water, 0.1 to 0.5% 0.05 to 0.15% by weight of magnesium sulfate (MgSO 4 ), 0.05 to 0.25% by weight of potassium monophosphate (KH 2 PO 4 ), 0.05 to 0.25% by weight of potassium diphosphate (K 2 HPO 4 ) .
The liquid culture in the step (a) can be performed under a blue LED light source and can be performed by maintaining the concentration of carbon dioxide at 1,000 to 2,000 ppm.
The liquid culture is carried out at 20 to 28 DEG C with hydrogen ion concentration (pH) of 4.5 to 6.0, light source of blue LED, illuminance of 0.1 to 0.8 LUX and air of 0.5 to 2.0 kgf / The concentration of carbon dioxide can be carried out for 8 to 13 days while maintaining the concentration at 1,000 to 2,000 ppm. Specifically, it may be carried out at a temperature of 20 to 25 ° C, a pH of 4.5 to 6.0, an air injection of 0.5 to 2.0 kgf /
As a parent strain in step (a), one of the excellent strains stored at 1-5 ° C. in a PDA (Potato dextrose agar) medium was inoculated into an Erlenmeyer flask using a PDB (Potato dextrose broth) ° C, and cultured for 7 to 9 days. At this time, the amount of the mycelium to be added to the inoculum is preferably about 0.5% (w / v) based on the amount of the solution to be cultured. Since the amount of extracellular polysaccharide is not so high as much as the amount of mycelium (% / 100 ml, w / v), the composition of the medium is not the best nutritional ratio and environmental condition for growth of the mycelium, It is preferable to apply selective culture conditions in which the cells are formed.
The culture solution can be separated and purified into mycelium and an aqueous solution. Specifically, the separated tablets can be purified by repeatedly removing the mycelium from the mycelium with a centrifugal separator (Multi-Sheet Filter Press) and a vibrating centrifugal separator (PALLSEP), and then irradiating ultraviolet rays (UV) for 1 minute . In addition, the culture solution can be kept sealed after removing oxygen. If the mycelium is present in the culture solution, the content of the active ingredient may be changed by growing mycelium.
In the step (b), the mycelial culture liquid prepared in the step (a) may be dried and pulverized. The drying may be carried out at a temperature of 40 DEG C or less, more specifically, at a temperature of 30 DEG C or less for 48 to 96 hours to prevent the disappearance of the active material. Also, in the step (b), it is preferable to use a vacuum freeze dryer rather than a vacuum dryer in which the evaporation temperature is set to be relatively high, since the change in effective substance content is minimized.
In step (c), the dry powder of the mycelial fluid obtained in step (b) is extracted with a solvent, and then the extracellular polysaccharide, which is an active ingredient of the composition according to the present invention, is isolated and prepared.
Specifically, 100 ml of distilled water was added to 3 to 10 g of the dried powder of the mycelial culture solution, the mixture was suspended well, and the mixture was centrifuged at 5,000 rpm to 10,000 rpm for 10 minutes to 30 minutes to obtain a supernatant. ~ 3 times the amount of the extraction solvent, and put in a refrigerator at 1 ~ 5 ℃ for 10 ~ 15 hours. The supernatant alone may be centrifuged at 5,000 rpm to 10,000 rpm for 10 minutes to 30 minutes, and then the precipitate may be recovered to prepare a crude extracellular polysaccharide. The extracellular polysaccharide may be lyophilized and dried at 30 DEG C or lower to obtain an extracellular polysaccharide.
The extraction solvent may be a solvent selected from the group consisting of water, a lower alcohol having 1 to 4 carbon atoms, acetone, ether, chloroform and ethyl acetate, or a mixture thereof. More specifically, water, methanol, ethanol, , Acetone and ethyl acetate, or a mixture thereof, and more preferably water or 50 to 100% (v / v) aqueous ethanol solution.
An extracellular polysaccharide produced by the cellulolytic enzyme of the present invention; A mycelial culture solution of ceriplora lacerata containing the extracellular polysaccharide; A dry powder of the mycelial culture liquid; Or an extract of the mycelial body fluid may be used as an additive for pharmaceutical composition and / or health functional food for the purpose of preventing hangover or hangover, As shown in FIG.
The extracellular polysaccharide may be contained in an amount of 0.1 to 80% by weight, or 0.1 to 50% by weight based on the total weight of the composition for hangover, and the extract of the mycelial culture solution, the dried powder thereof or the mycelial culture solution of the cellulolytic enzyme, It may be included in an amount corresponding to the content of the exopolysaccharide. More specifically, however, an extracellular polysaccharide; A culture fluid containing the same; A dry powder of the culture solution; Alternatively, the effective amount of the extract of the culture can be appropriately controlled depending on the method and purpose of use of the hangover remover composition.
The present invention also provides a pharmaceutical composition for prevention or elimination of hangover comprising the above-described composition for hangover drowning.
The pharmaceutical composition for preventing or eliminating the hangover showed a hangover resolution effect by decreasing the concentration of ethanol and / or acetaldehyde in the blood.
The pharmaceutical composition for prevention or elimination of hangover includes an extracellular polysaccharide produced by three lipolactacera; A culture solution of mycelium of Sellapora lacera rata containing the same; A dry powder of the mycelial culture liquid; Or an appropriate carrier, excipient and diluent which are conventionally used in addition to those containing the extract of the mycelial liquid as an active ingredient.
Each of the pharmaceutical compositions according to the present invention can be formulated according to a conventional method. Suitable formulations include, but are not limited to, tablets, pills, powders, granules, dragees, hard or soft capsules, solutions, suspensions or emulsions, injections, suppositories and the like.
The pharmaceutical composition according to the present invention can be prepared into a suitable formulation using a pharmaceutically inert organic or inorganic carrier. That is, when the formulations are tablets, coated tablets, dragees and hard capsules, they may include lactose, sucrose, starch or derivatives thereof, talc, calcium carbonate, gelatin, stearic acid or a salt thereof. Also, when the formulation is a soft capsule, it may include vegetable oils, waxes, fats, semi-solid and liquid polyols. Further, when the formulation is in the form of a solution or a syrup, it may contain water, polyol, glycerol, and / or vegetable oil.
The pharmaceutical composition according to the present invention may further contain preservatives, stabilizers, wetting agents, emulsifiers, solubilizers, sweeteners, coloring agents, osmotic pressure regulators, antioxidants and the like in addition to the above carriers.
The method of administering the pharmaceutical composition according to the present invention can be easily selected according to the formulation, and can be administered orally or parenterally. The dosage may vary depending on the patient's age, sex, weight, degree of pathology, and route of administration, but is generally in the range of 5 to 1,000 mg / kg body weight based on the extracellular polysaccharide, mg / kg body weight may be administered once or three times a day. However, the dose does not limit the scope of the present invention.
The pharmaceutical composition according to the present invention not only provides a good hangover resolution effect but also has little toxicity and side effects caused by drugs, so that it can be safely used for prolonged use for preventing hangover or hangover.
Further, the present invention provides a health functional food for hangover prevention or improvement comprising the above-described composition for hangover decay.
The health functional food according to the present invention may be in the form of a powder, a granule, a tablet, a capsule or a drink, and may be a candy, a chocolate, a gum, a tea, a vitamin complex,
Herein, the extracellular polysaccharide according to the present invention contained in the health functional food; A mycelial culture fluid containing the same; A dry powder of the mycelial culture liquid; Or the content of the extract of the mycelial culture liquid may be usually 0.01 to 50% by weight, or 0.1 to 20% by weight of the total food weight. Also, in the case of a health drink composition, it may be contained in an amount of 0.02 to 10 g, or 0.3 to 1 g, based on 100 ml of the health drink composition.
The food may be an extracellular polysaccharide of the present invention; A culture solution of mycelium of Sellapora lacera rata containing the same; A dry powder of the mycelial culture liquid; Or a food-acceptable food-aid additive together with the extract of the mycelial culture broth.
Also, the extracellular polysaccharide produced by the cellulolytic enzyme of the present invention; A culture solution of mycelium of Sellapora lacera rata containing the same; A dry powder of the mycelial culture liquid; Or the extract of the mycelial culture liquid may be used as an additive for various medicines, quasi-drugs and foods for the purpose of exhibiting a hangover prevention effect and / or a hangover effect, and the amount and the mode of use can be appropriately adjusted according to the purpose.
Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
[ Example ]
Manufacturing example
One.
Three Li Pori
Lacerata
Mycelial cultures, their dry powders, extracts and extracellular polysaccharides (
exopolysaccharide
; Hereinafter referred to as "EPS")
1.1 Three Li Pori Lacerata Production of Mycelial Culture Medium
The bacterium cultivated by subculture was stored frozen at -80 ℃ and stored in a PDA (Potato dextrose agar) medium (87 plastic culture (Hereinafter referred to as " PDA culture broth ") was stored in a refrigerator at 4 ° C for 2 to 3 times in a refrigerator (Difco, Becton Dickinson and Company). Then, 600 ml of a PDB (Potato dextrose broth) medium (Difco, Becton Dickinson and Company) was added to the Erlenmeyer flask. One PDB culture was added to the flask, followed by shake culture for 8 days to obtain a PDB culture.
Thereafter, a mixture of 1.5% by weight of sugar, 0.5% by weight of glucose, 0.5% by weight of potato starch, 0.25% by weight of water, 0.25% by weight of blood, 0.75% by weight of soybean meal, 0.05% by weight of magnesium sulfate (MgSO 4 ) 2 PO 4 ) 0.05% by weight potassium diphosphate (K 2 HPO 4 ) 0.05% by weight and water in the remaining amount was sterilized in an 800 L fermenter at a rate of 1.5 kgf /
1.2 Three Li Pori Lacerata Preparation of dried powder of culture medium
The cultured mycelium of Cerporaria lactamera prepared in Preparation Example 1.1 was vacuum-freeze-dried at 25 DEG C for 72 hours by using a vacuum freeze dryer to obtain a dry powder of a culture medium of the seripositive Lactacera mycelium.
1.3 Three Li Pori Lacerata Preparation of culture extract
100 ml of distilled water was added to 5 g of the dried powder of the culture medium of the cellulolytic enzyme solution prepared in Preparation Example 1.2, and the mixture was centrifuged at 8,000 rpm for 20 minutes. The supernatant was added 2 to 3 times Of ethanol was added and allowed to stand at 4 캜 for 12 hours. Thereafter, the supernatant was taken from the column, and an extract of the cultured Mycelium lacticera mycelium was prepared.
1.4 Three Li Pori Lacerata Preparation of EPS from culture medium
The extract of the culture medium of the cellulolyticase produced in Preparation Example 1.3 was further centrifuged at 8,000 rpm for 20 minutes and the precipitate was recovered to obtain crude EPS. The crude EPS was vacuum-lyophilized in a vacuum freeze dryer at 25 ° C for 72 hours to obtain an EPS produced by Sera lipolactacrata.
Example
1. Characterization of EPS
1.1 Gel Permeation Chromatography, GPC Molecular weight measurement of EPS using
The EPS prepared in Preparation Example 1 was dissolved in a solution of 0.1 M Na 2 SO 4 /0.05 M NaN 3 (pH adjusted to 4 with glacial acetic acid) to a concentration of 1% (w / v) After centrifugation for 0.5 hr, only the supernatant was filtered with a 0.45 탆 syringe filter and analyzed by GPC.
Specifically, the GPC analysis conditions were a refractive index as a detector, a GPC column as OHpak SB 805 HQ (Shodex, Japan) and a mobile phase as 0.1 M Na 2 SO 4 / 0.05 M NaN 3 , And the flow rate of the mobile phase was allowed to flow at a rate of 1.0 ml / min. Standard curves were prepared using dextran (American Polymer Corporation, USA) with different molecular weights (130 kDa, 400 kDa, 770 kDa or 1200 kDa) and refractive index (RI) Knauer K-2310 Germany) was used to measure the molecular weight of EPS. The measurement conditions are summarized in Table 1 below.
As a result, the molecular weight of the EPS of the present invention was about 120 kDa.
1.2 Measurement of sugar and protein content of EPS
The EPS prepared in Preparation Example 1 was subjected to second purification and treated with a protein hydrolyzing enzyme to measure sugar and protein content.
Specifically, the first purified EPS (EPS prepared in Preparation Example 1) was dissolved in distilled water and centrifuged at 8,000 rpm for 20 minutes to separate the supernatant. Then, the separated supernatant was diluted to 2 to 3 times its amount Ethanol was added and the mixture was placed in a refrigerator at 4 캜 for 12 hours. After the supernatant was centrifuged again at 8,000 rpm for 20 minutes, the precipitate was recovered and the second purified EPS was obtained. After the second purified EPS was dissolved in distilled water, the protein hydrolyzing enzyme alcalase was treated at a concentration of 0.5% (w / v) at 50 ° C for 30 minutes.
The sugar content was then measured by the phenol-sulfuric acid method. Specifically, 25 μl of 80% (v / v) phenol was added to 1 ml of diluted sample, and 2.5 ml of sulfuric acid was added. After cooling to room temperature, absorbance was measured at 465 nm and the sugar content was calculated.
Protein content was also measured by the BCA method (Smith PK et al., Analytical Biochemistry , 150 (1): 76-85, 1985) and bovine serum albumin was used as a standard.
The sugar content and the protein content measured as described above are shown in Table 2, and the sugar content was 45 to 51% by weight and the protein content was 33 to 34% by weight.
Also, as a result of analyzing sugar components of EPS, it was found that EPS mainly contains mannose, galactose and glucose.
Example
2. Verification of the hangover effect of mouse target
In order to evaluate the hangover resolution effect of the cultured mycelium of Cerporaria lacteras in Production Example 1.1, the concentration of blood alcohol was measured after treatment with various concentrations of a culture medium of three lipolylacerate mycelia after administering ethanol to a mouse.
Specifically, 7-week-old C57BL / 6J mice were used as an experimental animal, and the animals were allowed to freely eat solid feeds and tap water while being conditioned at a temperature of 21 ± 3 ° C, a relative humidity of 50 ± 5%, illumination of 200 to 300 lux, , And only healthy animals were selected and used for the test. During the adaptation period, the body weight of the healthy subjects was measured, and then 50 animals of average weight were selected. The animals were randomly divided into 5 groups of 10 rats, fasted for 18 hours before the experiment and fed only with water. The blood alcohol concentration was measured according to the administration time.
In the fasted group, only the distilled water was administered to the first group as the normal control group. In the second group, 40% (v / v) ethanol was orally administered in the amount of 5 g / kg body weight as the negative control group. The cultured mycelium of ceriplora lactaceras of Preparation 1.1 in an amount of 5 g / kg of body weight and 40% (v / v) ethanol and 100 mg / kg of body weight was orally administered. In the fourth group, 5 g / Kg of body weight of 40% (v / v) ethanol and 500 mg / kg of body weight was orally administered to the cultured mycelium of Cerplia lacera rata of Preparation 1.1. 1.5 ml of blood was collected from oral administration, immediately after oral administration, 30 minutes, 120 minutes and 300 minutes after oral administration, by heart sampling of control and experimental mice. The collected blood was analyzed for ethanol concentration (mM) in blood using Headspace-GC / MS (Perkin Elmer, clarus 600T). The results are shown in FIG.
As shown in FIG. 1, the ethanol concentration in the blood after 30 minutes of ethanol administration was 10.76% in the third group to which the culture medium of the present invention was added, compared with the ethanol-
Further, as a result of calculation of the area under the curve (AUC) of FIG. 1, the AUC of the second group was 1398.9 mM x min, the AUC of the third group was 1238.7 mM x min, and the AUC of the fourth group was 1195.05 mM × minute. As a result, it was confirmed that the concentration of ethanol in blood was decreased by 11.45% in the third group and by 14.57% in the fourth group, compared with the ethanol-only group.
This shows the effect of reducing the concentration of ethanol in the serum of the culture medium of the ceriplora lactaceras of the present invention, thereby showing the hangover resolution activity of the culture medium of the mycelium of ceriplora lactaceras of the present invention.
Example
3. Clinical Trial
In order to evaluate the hangover effect of the dry powder of the culture medium of the preparation of the cell culture of the preparation of Example 1.2, blood ethanol concentration (%) and clinical questionnaires were measured after drinking. The age and sex composition of the panel of this experiment are shown in Table 3 below.
Specifically, after consuming 1.5 g of ethanol / kg of body weight as a target for the panel, the dilution group contained 90.91% by weight of dry granulated cultivar cultures of the preparation of Example 1.2, 6.49% by weight of crystalline cellulose, 1.8% by weight of silicon dioxide, (550 ㎎ / tablet) mixed with 0.8% by weight of magnesium was orally administered in two tablets. In placebo, tablets (550 ㎎ / tablet) made by mixing lactose instead of three - lipid peroxidized culture medium Orally. Blood alcohol was measured immediately after drinking, 30 minutes, 60 minutes, 120 minutes and 16 hours after drinking. The alcohol concentration in the blood was measured using a breathalyzer to measure the blood concentration in the breath. Furthermore, a panel of clinical questionnaires was conducted 16 hours after drinking. Table 4 and FIG. 2 show the results of measurement of relative ethanol concentration in blood (%) based on 100% immediately after drinking, and Table 5 shows the average value of the results of the clinical question after 16 hours of drinking.
As shown in Table 4 and FIG. 2, the concentration of ethanol in the blood after drinking was 23.08% after 60 minutes of drinking as compared to placebo, 23.08% after drinking of the culture medium of the cellulolytic enzyme of the present invention, It is 9.23% lower after 120 minutes.
Furthermore, the area under the curve (AUC) of FIG. 2 was calculated. As a result, the AUC of the ampicillin group was 584.62% relative times and the AUC of the placebo group was 645.75% relative time. As a result, compared with the placebo group, it was confirmed that the herbal medicine group decreased blood alcohol concentration by 9.47%.
This shows that the ethanolic absorption of blood of the cultured mycelium of ceriplora lactaceras of the present invention is reduced, thereby showing the hangover resolution activity of the culture medium of the mycelium of ceriplora lactaceras of the present invention.
miscarriage of justice
Lowering
In Table 5, 1 means no or little inconvenience to life, 2 means little or no weakness in life, 3 means no physical discomfort in life, It is somewhat disturbed or generally severe, and 5 is very symptomatic, so it has many difficulties in living or very severe.
As shown in Table 5, as compared with the placebo group, the jean medicine group had the effect of alleviating the slack (24% improvement), alleviating the thirst (39% improvement) In the case of fatigue-related symptoms, the feeling of helplessness was alleviated (32% improvement), and the effect of alleviating drowsiness (43% improvement) was confirmed. In addition, compared with placebo, the Jin-Jin group improved symptoms (38% improvement) and decreased concentration (32% improvement) in weather related symptoms due to hangover. , And abdominal pain (33% improvement). Furthermore, Compared with placebo, Jin-In group was found to be effective in relieving headache (38% improvement) and dizziness (23% improvement) in the case of headache-related symptoms due to hangover.
From the above results, the culture medium of the mycelial growth medium of the present invention showed a marked improvement effect on hangover-related symptoms.
Claims (13)
Wherein the extracellular polysaccharide comprises 40-60 wt% sugar and 30-40 wt% protein and has a molecular weight of 100-150 kDa.
Wherein the extracellular polysaccharide comprises 43 to 47% by weight of sugar and 33 to 36% by weight of protein and has a molecular weight of 115 to 125 kDa.
Wherein the saccharide contains mannose, galactose and glucose.
Wherein the culture medium of the mycelium of the cellulolytic enzyme is prepared by liquid culture of mycelia of the cellulolytic enzyme.
The liquid medium for the culture is sugar, glucose, starch, water, for maekbun, soy flour, magnesium sulfate (MgSO 4), 1 potassium phosphate (KH 2 PO 4), 2 potassium phosphate (K 2 HPO 4) and water Wherein the hydrogen ion concentration is in the range of 4.5 to 6.0.
Wherein the liquid culture is carried out under a blue LED light source and is carried out by maintaining the concentration of carbon dioxide at 1,000 to 2,000 ppm.
Wherein the extracellular polysaccharide is contained in an amount of 0.1 to 80% by weight based on the total weight of the composition.
Wherein said health functional food is in the form of powder, granule, tablet, capsule or beverage.
The health functional food is a candy, chocolate, gum, tea, vitamin complex or health supplement food, a health functional food for preventing or improving hangover.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150141422A KR101655882B1 (en) | 2015-10-08 | 2015-10-08 | Composition for eliminating hangover comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
| PCT/KR2016/011183 WO2017061787A1 (en) | 2015-10-08 | 2016-10-06 | Composition for relieving hangovers containing extracellular polysaccharide produced from ceriporia lacerata as active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150141422A KR101655882B1 (en) | 2015-10-08 | 2015-10-08 | Composition for eliminating hangover comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101655882B1 true KR101655882B1 (en) | 2016-09-08 |
Family
ID=56950591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150141422A KR101655882B1 (en) | 2015-10-08 | 2015-10-08 | Composition for eliminating hangover comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101655882B1 (en) |
| WO (1) | WO2017061787A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101925096B1 (en) | 2018-05-02 | 2018-12-04 | 아미코젠주식회사 | A manufacturing method of hangover-eliminating enzyme powder and a composition for relieving hangover comprising thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100968109B1 (en) | 2008-01-15 | 2010-07-06 | 주식회사농심 | Calcium?compound containing natural product composition for curing a hangover and preparation method thereof |
| KR101031605B1 (en) | 2010-11-11 | 2011-04-27 | 김병천 | Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same |
| KR101444614B1 (en) * | 2013-08-01 | 2014-09-26 | 계명대학교 산학협력단 | Method for producing fermented material with high GABA by mixed culture of Ceriporia lacerata and Lactobacillus |
| KR101522415B1 (en) * | 2015-02-26 | 2015-05-21 | 한상선 | Cosmetic composition including an acanthus extract of ceriporia lacerata and cosmetics using the same |
| KR20150103690A (en) * | 2013-01-18 | 2015-09-11 | (주)퓨젠바이오농업회사법인 | Method for preparing extract from culture medium of ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic diseases and diabetic complications, which contains extract from culture medium of ceriporia lacerata as active ingredient |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140193454A1 (en) * | 2013-01-09 | 2014-07-10 | Byoung Cheon KIM | Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient |
-
2015
- 2015-10-08 KR KR1020150141422A patent/KR101655882B1/en active IP Right Grant
-
2016
- 2016-10-06 WO PCT/KR2016/011183 patent/WO2017061787A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100968109B1 (en) | 2008-01-15 | 2010-07-06 | 주식회사농심 | Calcium?compound containing natural product composition for curing a hangover and preparation method thereof |
| KR101031605B1 (en) | 2010-11-11 | 2011-04-27 | 김병천 | Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same |
| KR20150103690A (en) * | 2013-01-18 | 2015-09-11 | (주)퓨젠바이오농업회사법인 | Method for preparing extract from culture medium of ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic diseases and diabetic complications, which contains extract from culture medium of ceriporia lacerata as active ingredient |
| KR101444614B1 (en) * | 2013-08-01 | 2014-09-26 | 계명대학교 산학협력단 | Method for producing fermented material with high GABA by mixed culture of Ceriporia lacerata and Lactobacillus |
| KR101522415B1 (en) * | 2015-02-26 | 2015-05-21 | 한상선 | Cosmetic composition including an acanthus extract of ceriporia lacerata and cosmetics using the same |
Non-Patent Citations (2)
| Title |
|---|
| J. Caballeria, et al., Life Sci., 41, 1021-1727, 1986 |
| K. Ebihara et al., Agri. Biol. Chem., 52, 1311, 1988 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101925096B1 (en) | 2018-05-02 | 2018-12-04 | 아미코젠주식회사 | A manufacturing method of hangover-eliminating enzyme powder and a composition for relieving hangover comprising thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017061787A1 (en) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4669920B2 (en) | Functional material that suppresses blood glucose rise and blood pressure rise | |
| CN104982928B (en) | A kind of japanese yew fruit health care ferment and preparation method thereof | |
| JP5937596B2 (en) | Urushi extract with increased content of active flavonoid compound and method for producing the same | |
| KR20160008425A (en) | Composition for improvement of liver function comprising exopolysaccharide derived from ceriporia lacerata culture broth extracts as an active ingredient | |
| KR101729003B1 (en) | Composition For Preventing or Treating Gout Containing Extracts or Fermentation Metabolites of Dendropanax morbiferus | |
| KR101371143B1 (en) | Composition comprising chlorella for improving liver function or relieving hangover | |
| KR101655882B1 (en) | Composition for eliminating hangover comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| KR101737627B1 (en) | Antioxidant composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| KR20160008431A (en) | Composition for improvement of lipid-related metabolic function comprising exopolysaccharide derived from ceriporia lacerata culture broth extracts as an active ingredient | |
| US20010034325A1 (en) | Dietary modulators of gamma glutamyl transpeptidase | |
| KR101237215B1 (en) | Phamaceutical composition for prevention or treatment of enteritis | |
| KR101712590B1 (en) | Composition for relieving fatigue comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| US20230404964A1 (en) | Combination for reducing oxidative stress in the body and maintaining liver functions | |
| JP2009274961A (en) | Absorption promoter | |
| KR20140017933A (en) | Composition comprising fermented extract of trifoliate orange for improving diabetes | |
| CN112007092A (en) | Anti-alcohol composition and preparation method thereof | |
| JP5118333B2 (en) | New antioxidant lignan compounds | |
| KR101734909B1 (en) | Novel use of Limonium tetragonum | |
| KR101691972B1 (en) | Pharmaceutical composition for the prevention or treatment of a cancer comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| KR100721983B1 (en) | A method of extracting a d-ounitol from Lespedeza cuneata and functional goods containing extracts | |
| KR100824365B1 (en) | Composition comprising the extracts, fractions and the isolated compounds of phyllostachys nigra munro for prevention or treatment of diabetic complications | |
| JP2003012538A (en) | Antioxidant agent | |
| CN104162163A (en) | Application of acyl-coenzyme A oxidase as therapeutic target of diabetes | |
| KR100494871B1 (en) | Extracts of CHAGA mushroom showing antioxidant and lipid metabolic activity, the extraction method and the use thereof | |
| KR102523928B1 (en) | Compositon for Improving Memory Containing Culture Extract of Bacillus Subtilis Natto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20190903 Year of fee payment: 4 |